Just out at @JPubEcon w/ Colleen Carey and Michael Daly @HealthEcon_CU:. (ungated). What does #cancer drug marketing to physicians do? We find it increases #expenditure on drug prescribing by about 4% with no improvement in patient #mortality.

RT @amydiehl: In a study of professors, women got 378 new work requests over 4 wks vs 118 for men. Women spent more time on service, advisi….

RT @nberpubs: Families responded to pronounced full-day kindergarten expansions across the US over three decades with increases in employme….

RT @AEAjournals: Forthcoming in the JEL: "Difference-in-Differences Designs: A Practitioner’s Guide" by Andrew Baker, Brantly Callaway, Sco….

RT @JohnHolbein1: Nice.

RT @wschpero: Please help spread the word!. We at the Cornell Health Policy Center are excited to launch our Data-Driven Journalism Series,….

Our new @nberpubs wp links experimentally measured #altruism of physicians to their industry payments and drugs prescribed. We find that non-altruistic docs both receive higher payments and more likely to respond by increasing branded drug prescribing than altruistic docs.

Special thanks to @TheWonkologist for very helpful discussions and insights! .#UWCHOICE @UW_Pharmacy.

Our study sheds light on the impact of marketing encounters between drug companies and physicians on efficiency in healthcare spending and patient health, particularly in cancer care treatments w/ high prices and potentially small survival benefits.

We find physicians expand the drug treatment to healthier patients after marketing encounter, with no improvement in overall patient mortality. Our estimates can not reject INCREASES in patient mortality.

We find that initiation of financial relations leads to an increase in Part B cancer drug expenditure of about 4%, though the effect fades in about a year. This translates to a rate of return of over 800% on marketing encounters for cancer drug companies.

Using Medicare Part B claims linked with the CMS Open Payments Data, we examine the impact of marketing encounter w/ financial transfer between cancer drug companies and physicians on cancer drug prescribing and patient mortality.

RT @jenniferdoleac: Academic job market candidates:. Did you know you can "make your own post-doc" by applying for external research fundin….

New in @Health_Affairs led by #UWCHOICE postdoc Donghoon Lee: using a Regression Discontinuity design, we find that Medicare enrollment at age 65 increased visits to primary care providers but NOT mental healthcare providers.

RT @LaurawherryR: Happy ERP day! The 2025 Economic Report of the President is out now! Chapters cover a wide range of topics incl. remote….

RT @biancafrogner: Sign up to hear the latest work of a wonderful set of researchers including: Jiani Yu @WeillCornell, Clara Scher @Rutger….

RT @Zhuoer_Lin: Is childhood school racial segregation associated with late-life cognitive outcomes? Our latest work in @JAMANetworkOpen li….

RT @gupta_atulk: Wishing everyone a happy new year! . Also, a reminder to send your papers to AHEC! All topics within health econ are welco….

RT @paul_gertler: Check out new publication with @tadejagracner and @claireeboone on long term health effects of excess sugar in utero and….

RT @paul_gertler: Very nice paper on important topic us @ShacharKariv and @JingLiUW ….